GC Biopharma

GC Biopharma ROCE

The Return on Capital Employed (ROCE) of GC Biopharma (006280.KS) as of Oct 25, 2026 is 4.96 %. In the previous year, Return on Capital Employed (ROCE) was 2.17 % — a change of 128.77% (higher).

ROCE

4.96 %

YoY

128.77%

Last updated:

In 2025, GC Biopharma's return on capital employed (ROCE) was 4.96 %, a 128.77% increase from the 2.17 % ROCE in the previous year.

The GC Biopharma ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
4.46 KRW
Jan 1, 2019
3.40 KRW
Jan 1, 2020
3.96 KRW
Jan 1, 2021
4.92 KRW
Jan 1, 2022
6.42 KRW
Jan 1, 2023
2.24 KRW
Jan 1, 2024
2.17 KRW
Jan 1, 2025
4.96 KRW
The GC Biopharma ROCE history
YEARROCEYoY
4.96 %+128.77%
2.17 %-3.07%
2.24 %-65.19%
6.42 %+30.68%
4.92 %+24.10%
3.96 %+16.41%
3.40 %-23.72%
4.46 %-45.22%
8.14 %+9.94%
7.41 %-19.36%
9.19 %-12.78%
10.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling GC Biopharma's Return on Capital Employed (ROCE)

GC Biopharma's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing GC Biopharma's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

GC Biopharma's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in GC Biopharma’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about GC Biopharma stock

Return on Capital Employed (ROCE) of GC Biopharma is 4.96 % in 2025.

Return on Capital Employed (ROCE) of GC Biopharma changed from 2.17 % to 4.96 %, representing a 128.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s GC Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — GC Biopharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — GC Biopharma